Press Releases

Press Releases

Date Title and Summary Additional Formats
Toggle Summary EDAP Submits 510(k) Application for FDA Clearance of Focal One HIFU
LYON, France , April 06, 2016 (GLOBE NEWSWIRE) -- EDAP TMS SA (Nasdaq:EDAP), the global leader in therapeutic ultrasound, today announced that it has submitted a 510(k) application to the U.S. Food and Drug Administration (FDA) for the clearance of its next generation HIFU device: the Focal One ® .
View HTML
Toggle Summary EDAP Reports 20% Revenue Growth to EUR 32.3 Million and EUR 0.5 Million Operating Profit for Full-year 2015
Obtained FDA clearance in November 2015 for Ablatherm Robotic HIFU; Fourth quarter 2015 HIFU Division revenues tripled over fourth quarter 2014; Overall fourth quarter 2015 revenues increased 82% over 2014 to EUR 11.8 million ( USD 12.8 million ); Solid cash position of EUR 14.6 million ( USD 15.8
View HTML
Toggle Summary EDAP to Report Fourth Quarter and Full Year 2015 Results on April 4, 2016
Conference Call and Webcast Scheduled for 8:30 a.m. ET
View HTML
Toggle Summary EDAP HIFU Advancements Highlighted at International Symposium on Therapeutic Ultrasound
LYON, France , March 22, 2016 (GLOBE NEWSWIRE) -- EDAP TMS SA (Nasdaq:EDAP), the global leader in therapeutic ultrasound, announced today that its advancements in High Intensity Focused Ultrasound (HIFU) were highlighted at the International Symposium on Therapeutic Ultrasound (ISTU 2016), which
View HTML
Toggle Summary EDAP HIFU and Lithotripsy Devices Showcased at 31st Annual European Association of Urology Congress
LYON, France , March 17, 2016 (GLOBE NEWSWIRE) -- EDAP TMS SA (Nasdaq:EDAP), the global leader in therapeutic ultrasound, today announced that its HIFU and lithotripsy devices were highlighted at the European Association of Urology (EAU) 2016 Annual Congress held in Munich, Germany , on March
View HTML
Toggle Summary EDAP Announces Sylvester Comprehensive Cancer Center in Miami as First Certified U.S. Ablatherm® Robotic HIFU Site
LYON, France , March 10, 2016 (GLOBE NEWSWIRE) -- EDAP TMS SA (Nasdaq:EDAP), the global leader in therapeutic ultrasound, today announced that Sylvester Comprehensive Cancer Center at the University of Miami is the first site in the U.S. to be fully certified in the use of Ablatherm Robotic HIFU.
View HTML
Toggle Summary First Patients Treated With EDAP's Ablatherm® Robotic HIFU in New York
Procedures Performed at Gramercy Surgery Center by Dr. Ivan Grunberger, Assisted by Dr. Judd Boczko
View HTML
Toggle Summary First Prostate Ablation Treatments Performed Using EDAP's FDA Approved Ablatherm® Robotic HIFU at Sylvester Comprehensive Cancer Center, in Miami, Florida
LYON, France , Jan. 25, 2016 (GLOBE NEWSWIRE) -- EDAP TMS SA (Nasdaq:EDAP), the global leader in therapeutic ultrasound, today announced the first prostate ablation treatments performed at Sylvester Comprehensive Cancer Center , Miami , using FDA approved Ablatherm Robotic HIFU.
View HTML
Toggle Summary EDAP Announces Results of World's First Focal HIFU Trial
100% Cancer Specific Survival, 94% Continence Preservation and 80% Potency Preservation
View HTML
Toggle Summary EDAP Receives Japanese Approval for Quanta Litho Laser; Secures Exclusive Distribution Rights in Japan
LYON, France , Jan. 06, 2016 (GLOBE NEWSWIRE) -- EDAP TMS SA (Nasdaq:EDAP), the global leader in therapeutic ultrasound, today announced that its Japanese subsidiary, Edap Technomed Japan, has secured Japanese PMDA approval for the Quanta Litho Laser.
View HTML